DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Positive impactCompany

Dr. Reddy's Laboratories Limited — Press Release

NSE 1 hr ago·5 Nov 2026, 4:21 am

Dr. Reddy's Laboratories

Dr. Reddy's Laboratories has received marketing authorization for a generic version of semaglutide in Brazil. This approval allows the company to sell the drug, which is used to treat Type 2 diabetes, in the Brazilian market.

This development is significant for investors as it expands the company's global footprint and revenue streams. Semaglutide is a high-demand product, and gaining access to the Brazilian market is a strategic win for Dr. Reddy's.

Investors should monitor the company's future updates regarding the launch timeline and sales projections in Brazil. The actual uptake of the drug will be key to understanding the financial impact of this authorization.

Affected stocks

Bullish1 stock

Dr. Reddy's Laboratories

DRREDDY Bullish

₹1,374.00

Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.

Key takeaways

Concerns Dr. Reddy's Laboratories (DRREDDY).
Category: Company.
AI reads the tone as positive (potentially bullish) for the stock.

Why it matters

A routine update for Dr. Reddy's Laboratories. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at NSE.